Further Mixed Results For GSK/Theravance’s Relovair Have Investors Holding Breath
This article was originally published in The Pink Sheet Daily
Executive Summary
GSK and Theravance released preliminary results of two Phase III studies for their COPD drug Relovair that could serve to help differentiate the drug from Advair.